The information on this cover page is based on the most recent submission data from the authors. It may vary from the final published article. Any fields remaining blank are not applicable for this manuscript.

**Article Type:** Perspective

**Tribute to Barbara Murphy**

**DOI:** 10.34067/KID.0005002021

Steven Coca

**Key Points:**

* *

* *

* *

**Abstract:**

**Disclosures:** S.G. Coca has received fees for advisory boards or steering committee roles for Renalytx, CHF Solutions, Bayer, Boehringer Ingelheim, Takeda, Relypsa (Vifor), Quark, ProKidney, and Akebia in the past 3 years. He owns equity in Renalytx; receives salary and research support from Renalytx, ProKidney, XORTX, and the Renal Research Institute

**Funding:**

**Author Contributions:** Steven Coca: Conceptualization; Writing - original draft

**Clinical Trials Registration:** No

**Registration Number:**

**Registration Date:**

**How to Cite this article:** Steven Coca, Tribute to Barbara Murphy, Kidney360, Publish Ahead of Print, 10.34067/KID.0005002021
Tribute to Barbara Murphy

Steven G. Coca

Department of Medicine, Division of Nephrology, Icahn School of Medicine at Mount Sinai, New York, NY, USA

Corresponding Author:
Steven Coca, DO, MS
Department of Internal Medicine
Icahn School of Medicine at Mount Sinai
One Gustave L. Levy Place, Box 1243
New York, NY 10029
Tel: (212) 241-6633
This is a tribute to the late Dr. Barbara T. Murphy, the Murray M. Rosenberg Professor of Medicine and Chair of Medicine at the Icahn School of Medicine at Mount Sinai in New York City, the Dean for Clinical and Population Management, Councilor and the President-Elect for the American Society of Nephrology.

Accounts of Dr. Murphy’s many accomplishments have already been detailed in other glowing tributes. One of her most notable feats was that in 2012, she became the first female Chair for a major academic center in New York City and, at the time, was only the second female Chair of any Department at a top 20 medical school in the United States. During the 9 years with Dr. Murphy at the helm, the prestige and accomplishments of the Department of Medicine also grew. For example, funding levels per year placed the Mount Sinai Department of Medicine in the top 15th among graduate medical departments in the country.

Dr. Murphy’s research focused on genetics and genomics in transplantation. Using high-throughput genomic technologies, she generated data that increased the understanding of the immune mechanisms that lead to kidney graft rejection, injury and loss. Importantly, she aimed to identify gene expression profiles or genetic variants that would predict patients’ risk for disease and identified genetic drivers of fibrosis.

More than the leadership and her science, however, was the person, the human being that was Barbara T. Murphy. Most, if not all Department Chairs, are driven, hard-working, and prolific. However, the President-Elect of the American Society of Nephrology was not an ordinary department chair. One could argue that any immigrant who rose to such ranks must have tales of the fortitude needed to reach such high stature. Indeed, the fact that she as an immigrant woman, no less became the first woman to serve as chair of medicine in New York, evokes visions of breaking down doors and shattering glass ceilings.

How can anyone who had not spent much time with Dr. Murphy, at Mount Sinai or on committees alongside her, have a humanistic glimpse as to what made her tick and led to her vast successes? Those who did know her know that she had an ebullient personality and a sliver tongue that could deliver timely quips in all settings - from the highest level of national scientific conferences, with an incisive question or observation, to the post-meeting setting over drinks at a restaurant or bar. No man or woman, regardless of their stature, wealth or bravado, could intimidate Dr. Murphy. She rose to confront all such challenges continually, placing flags in the ground to indicate that she was ready, willing and able, regardless of looming or ominous barriers. Her piercing eyes flickered with an electric energy. He mind was always spinning and thinking. She could not and would not be outwitted, outplayed, outmaneuvered.

Like a great general on the battlefield, she anticipated where things needed to go. She certainly was not reactionary in nature. Instead, she was the epitome of proactivity. Despite her in-depth knowledge of transplant immunology and gene expression pathways, she was just as comfortable talking about health policy, public health, and epidemiology of kidney disease. Several years ago, she thought “big data” techniques would be important, before most people even knew how to define big data. She strongly desired “population scale population health”. Whether it was a personal chip on her shoulder from her memories as a 4 year old in Ireland being told she was not smart enough or good enough, or whether it was the institutional chip on Mount Sinai’s shoulder from being a “stand-alone” medical school in NYC without a hefty endowment, or whether it was fighting for patients with kidney disease who had all too often been ignored by pharma, foundations and the government for the sexier cardiology or oncology,
she was fierce in all her approaches to drive change, and improve health care delivery and outcomes.

It was in these efforts (improving health care delivery and outcomes), in which her ferocity was second to none. She abhorred the fact that so many patients were early stages of kidney disease were vastly ignored\textsuperscript{10} and insufficiently treated,\textsuperscript{11} and that so many patients started long-term dialysis without sufficient lead-time, proper planning, initiated in an acute setting.\textsuperscript{12} She was determined to tackle this problem, and she vociferously organized internal teams at Mount Sinai to address this ongoing issue, and bolstered her efforts for broader paradigm change with her Directorship role with Renalytix,\textsuperscript{13} and most certainly, her imminent role as ASN President.\textsuperscript{2}

No one dared stand in her way of her goals. Indeed, my jaw was left agape on more than one occasion as she “virtually assassinated” those who dared to question her aspirations for changing the status quo. She delivered precision blows that sent these challengers or naysayers reeling...she was the real life Arya Stark in background, operating with the grace of Sansa Stark at the podium. She was a true “protector of the realm”. Alas, her sword was not made of Valerian Steel, but rather her cunning words sent through cyberspace via email or text, or launched tersely from her mouth, with her enchanting Irish brogue. Yet, like all true great leaders, she had the wisdom and humility to listen, adapt, and change her viewpoint, when it was appropriate. That aptitude of hers is what makes me smile the most; best exemplified by a story and journey to be told at a future time, that began as her sniping “no way…never…a waste of time” to, within a matter of a months, gleefully exclaiming, “this is incredible…best decision ever…with a delightful group of people.”

The greatest tragedy is that she had to endure her final year in the midst of the pandemic. She was largely apart from those in the Mount Sinai community that yearned to see her again, to get a glimpse into her eyes, to share one last laugh or zinger with her. She was truly considered a real-life hero by her colleagues and trainees - particularly by so many young women in medicine whom she mentored, advised and inspired locally and from afar. While Dr. Murphy’s “watch has ended”, her trailblazing legacy and extreme passion to improve kidney and health care will live on in many ways,\textsuperscript{14} but forever in our hearts and minds. Indeed, \textit{Valar dohaeris}.\textsuperscript{15}

REFERENCES:

1. Dr. Barbara Murphy, Kidney Transplant Expert, Dies at 56, <https://www.nytimes.com/2021/07/03/health/dr-barbara-murphy-dead.html>
2. Barbara T. Murphy, MD, MB, BAO, BCh, FRCPI, <https://www.asn-online.org/about/memoriam.aspx?ID=151>
3. Barbara Murphy obituary: Leading kidney transplant expert with passion for research, <https://www.irishtimes.com/life-and-style/people/barbara-murphy-obituary-leading-kidney-transplant-expert-with-passion-for-research-1.4614873>
4. Message from the Chair, <https://icahn.mssm.edu/about/departments/medicine/chair-message>
5. Zhang, W. et al. A Peripheral Blood Gene Expression Signature to Diagnose Subclinical Acute Rejection. \textit{J Am Soc Nephrol} \textbf{30}, 1481-1494, doi:10.1681/ASN.2018111098 (2019).
Zhang, W. et al. Pretransplant transcriptomic signature in peripheral blood predicts early acute rejection. JCI Insight 4, doi:10.1172/jci.insight.127543 (2019).

O'Connell, P. J. et al. Biopsy transcriptome expression profiling to identify kidney transplants at risk of chronic injury: a multicentre, prospective study. Lancet 388, 983-993, doi:10.1016/S0140-6736(16)30826-1 (2016).

Li, L. et al. Novel Therapeutics Identification for Fibrosis in Renal Allograft Using Integrative Informatics Approach. Sci Rep 7, 39487, doi:10.1038/srep39487 (2017).

Menon, M. C. et al. Intrinsic locus determines SHROOM3 expression and potentiates renal allograft fibrosis. J Clin Invest 125, 208-221, doi:10.1172/JCI76902 (2015).

Szczech, L. A. et al. Primary care detection of chronic kidney disease in adults with type-2 diabetes: the ADD-CKD Study (awareness, detection and drug therapy in type 2 diabetes and chronic kidney disease). PLoS One 9, e110535, doi:10.1371/journal.pone.0110535 (2014).

Tummalapalli, S. L., Powe, N. R. & Keyhani, S. Trends in Quality of Care for Patients with CKD in the United States. Clin J Am Soc Nephrol 14, 1142-1150, doi:10.2215/CJN.00060119 (2019).

System, U. S. R. D. 2020 USRDS Annual Data Report: Epidemiology of kidney disease in the United States. (National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD).

Directorate Change, <https://investors.renalytix.com/news-releases/news-release-details/directorate-change>

Mount Sinai Announces First-of-its-Kind Center For Post-COVID Care, <https://www.mountsinai.org/about/newsroom/2020/mount-sinai-announces-first-of-its-kind-center-for-post-covid-care-pr>

valar dohaeris, <https://www.duolingo.com/dictionary/High%20Valyrian/valar%20dohaeris/4cf038b3c0d86891dd17210dea23691d>